Truist Securities analyst Nicole Germino reiterated a Buy rating and $22.00 price target on Sangamo BioSciences (NASDAQ: SGMO) after talking ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Sangamo BioSciences (SGMO) Potential Fair Value Goes to $32/Share on BMRN CRL - Truist SecuritiesAugust 19, 2020 1:02 PM Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)August 19, 2020 9:26 AM Sangamo Therapeutics (SGMO) Gains on BioMarin (BMRN) CRLAugust 19, 2020 9:13 AM